Use of Neoadjuvant Vandetanib in Aggressive Pediatric Medullary Thyroid Carcinoma. JCO precision oncology Kothari, R., Kreimer, S., Nadel, H., Seeley, H., Hartman, G., Meister, K. D. 2024; 8: e2300257

Abstract

Novel use of vandetanib in a child with aggressive MTC with prolonged response to treatment.

View details for DOI 10.1200/PO.23.00257

View details for PubMedID 38207224